Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Secord AA, O'Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenzel L, Gourley C. Gershenson DM, et al. Among authors: moore kn. Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9. Lancet. 2022. PMID: 35123694 Free PMC article. Clinical Trial.
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
Fader AN, Nagel C, Axtell AE, Zanotti KM, Kelley JL, Moore KN, Secord AA, Walsh CS, Huh WK, Gehrig PA, Gibbons H, Rose PG, Havrilesky LJ, Tuller E, Drake RD, Bottsford-Miller J, O'Malley DM; UPSC Consortium. Fader AN, et al. Among authors: moore kn. Gynecol Oncol. 2009 Mar;112(3):558-62. doi: 10.1016/j.ygyno.2008.11.016. Epub 2009 Jan 1. Gynecol Oncol. 2009. PMID: 19118888
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O'Malley DM, Tuller ER, Rose PG, Havrilesky LJ, Moore KN, Huh WK, Axtell AE, Kelley JL, Zanotti KM; UPSC Consortium. Fader AN, et al. Among authors: moore kn. Gynecol Oncol. 2009 Nov;115(2):244-8. doi: 10.1016/j.ygyno.2009.07.030. Epub 2009 Aug 26. Gynecol Oncol. 2009. PMID: 19712966
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian C. Alvarez EA, et al. Among authors: moore kn. Gynecol Oncol. 2013 Apr;129(1):22-7. doi: 10.1016/j.ygyno.2012.12.022. Epub 2012 Dec 20. Gynecol Oncol. 2013. PMID: 23262204 Clinical Trial.
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
Landrum LM, Brady WE, Armstrong DK, Moore KN, DiSilvestro PA, O'Malley DM, Tenney ME, Rose PG, Fracasso PM. Landrum LM, et al. Among authors: moore kn. Gynecol Oncol. 2016 Feb;140(2):204-9. doi: 10.1016/j.ygyno.2015.11.024. Epub 2015 Nov 23. Gynecol Oncol. 2016. PMID: 26616225 Free PMC article. Clinical Trial.
Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA. Dao F, et al. Among authors: moore kn. Gynecol Oncol. 2016 May;141(2):260-263. doi: 10.1016/j.ygyno.2016.03.010. Epub 2016 Mar 11. Gynecol Oncol. 2016. PMID: 26968641 Free PMC article.
331 results